Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Monopar Therapeutics Inc.NASDAQ: MNPR

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $3.89M (cash outflow) rose 48.3% year over year, ahead of the -9.6% change in trailing-twelve-month net income. Sequentially, it fell 25.1% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.

Context

  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 8 analysts of -$20.16M (+47.0%) for the fiscal year ending Dec 2026, a step up from the -12.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.89M-25.1% QoQ
Last fiscal yearDec 2025
-$13.72M-12.0% YoY
LTMMar 2026
-$14.98M-9.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.3%+108.9%+60.6 pp
1 year-12.0%+47.0%+59.0 pp
3-year CAGR+9.3%+13.1%+3.9 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(13.72M) USD
Year-over-year change
+12.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MNPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.6% is the 9th highest of 11, against a peer median of +15.3%.
  • Over three fiscal years its annual growth of +9.3% compares with a peer median of +0.9%.
MNPR Competitors
Net Income for MNPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMNMImmunome, Inc.LTM Sep 2026$282.65M USD+26.9%+79.2%—
BCYCBicycle Therapeutics plcLTM Mar 2026$218.8M USD+7.2%+24.8%344.6%
ADCTADC Therapeutics S.A.LTM Mar 2026$136.99M USD-8.6%-3.2%173.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$88.87M USD-31.7%-6.3%—
XNCRXencor, Inc.LTM Jun 2026$71.19M USD-60.8%+18.5%67.8%
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$68.17M USD+23.5%+19.2%—
IPHAInnate Pharma S.A.FY2025€49.18M EUR-0.6%-5.4%1764.5%
ZYMEZymeworks Inc.LTM Sep 2026$43.31M USD+168.3%—16.3%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$14.98M USD-9.6%+9.3%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$11.31M USD+127.6%+0.9%32.2%
Peer median (excluding MNPR) —+15.3%+0.9%67.8%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation1.47M1.64M1.9M1.14M4.84M
Change in Working Capital317.77K1.65M(1.35M)3.49M(2.61M)
Accounts Receivables00000
Inventory00000
Accounts Payables403.97K1.48M(1.33M)506.79K388.22K
Other Working Capital(86.2K)167.52K(20.41K)2.98M(2.99M)
Other Non-Cash Items0004.55M(716.46K)
Operating Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)
Capital Expenditures10000
Acquisitions (Net)00000
Purchases of Investments0(4.92M)(7.88M)(15.32M)(87.15M)
Sales of Investments0012.81M985.73K23.7M
Other Investing Activities00000
Investing Cash Flow0(4.92M)4.93M(14.34M)(63.45M)
Debt Repayment00000
Common Stock Issued10.93M109.34K2.07M59.4M127.71M
Common Stock Repurchased0000(35M)
Dividends Paid00000
Other Financing Activities(45.78K)(76.46K)(46.97K)(104.14K)(1.13M)
Financing Cash Flow10.88M32.87K2.03M59.29M91.57M
Effect of Forex Changes4.62K(3.48K)(16.8K)49497.27K
Net Change in Cash3.57M(12.12M)(920.11K)38.55M16.02M
Free Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.